含优化剂量利福平与莫西沙星的药物敏感肺结核治疗方案:一项开放标签随机III期实用性试验方案(OptiRiMoxTB)
该III期开放标签随机试验将在四个非洲国家纳入414例新诊断药物敏感肺结核成人,按胸片空洞分层后1:1:1随机分为两组4个月优化剂量利福平(35 mg/kg)方案(含或不含莫西沙星400 mg)和6个月标准治疗组,评估无结核生存与严重不良事件比例,并评价结核分枝杆菌分子细菌载量检测(TB-MBLA)用于微生物学疗效监测。
要点
- 4个月方案含利福平35 mg/kg,含或不含莫西沙星400 mg,对照为6个月标准治疗。
- 主要结局为无结核生存(疗效)和严重不良事件比例(安全性)。
- 次要结局包括评价TB-MBLA用于微生物学治疗监测。
核心结论
- 本研究将评估含优化剂量利福平(含或不含莫西沙星)的4个月多药方案在非洲药物敏感肺结核患者中疗效与安全性是否非劣于标准治疗。
研究设计与样本
- 多中心III期随机开放标签临床试验,在加蓬、马拉维、莫桑比克和坦桑尼亚四个非洲国家开展。
- 共纳入414例新诊断并签署知情同意的成人参与者,按胸片空洞分层后进行区组随机,按1:1:1分配至两个试验组和一个对照组。
主要发现
- 第一试验组接受优化剂量利福平35 mg/kg联合常规体重分段剂量的异烟肼、吡嗪酰胺和乙胺丁醇,每日一次,疗程4个月。
- 第二试验组接受优化剂量利福平35 mg/kg和莫西沙星400 mg每日一次,联合常规剂量异烟肼和吡嗪酰胺。
- 对照组接受6个月标准治疗:利福平10 mg/kg联合体重分段剂量的异烟肼、吡嗪酰胺和乙胺丁醇治疗2个月,随后相同剂量的利福平和异烟肼治疗4个月。
- 参与者随访至获得疗效(无结核生存)和安全性(严重不良事件比例)结局。
- 次要结局还包括评价结核分枝杆菌分子细菌载量检测(TB-MBLA)用于微生物学治疗监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current combination antibiotic treatment for drug-susceptible tuberculosis (DS-TB) usually takes 6 months to complete. This long duration can compromise clinical outcomes. Although a 4-month regimen including an optimized dose of rifapentine plus moxifloxacin is non-inferior to standard therapy, rifapentine is hard to source globally and adoption of this regimen has been slow. This trial investigates the efficacy and safety of a 4-month DS-TB treatment including the more readily available rifamycin, rifampicin 35 mg/kg, with or without moxifloxacin 400 mg. METHODS: This multi-centre phase III randomized open-label clinical trial will be conducted across four African countries (Gabon, Malawi, Mozambique and Tanzania). A total of 414 newly diagnosed consenting adult participants will be block randomized, after stratification by chest radiograph cavitation, to two experimental and one control arm at a ratio of 1:1:1. The first experimental group will receive optimized dose rifampicin (35 mg/kg) with routine weight-banded doses of isoniazid, pyrazinamide, and ethambutol once daily for 4 months. The second experimental group will receive optimized dose rifampicin (35 mg/kg) and moxifloxacin 400 mg once daily alongside routine doses of isoniazid and pyrazinamide. The control group will receive 6-month standard of care therapy: rifampicin (10 mg/kg) plus weight-banded dose of isoniazid, pyrazinamide, and ethambutol for 2 months, followed by the same doses of rifampicin and isoniazid for 4 months. Participants will be followed until the allocation of efficacy (TB-free survival) and safety (proportion of severe adverse events) outcomes. Secondary outcomes will also include the evaluation of the Tuberculosis Molecular Bacterial Load Assay (TB-MBLA) for microbiological treatment monitoring. DISCUSSION: This study will evaluate whether 4-month duration multi-drug treatment including an optimized dose of rifampicin with or without moxifloxacin has non-inferior efficacy and safety outcomes compared to standard of care DS-TB therapy in Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT05575518. Registered on 10th October 2022.
引用
- Mlyuka HJ, Liyoyo A, Nyaulingo B, et al. A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB). Trials. 2026. PMID: 41612490. doi:10.1186/s13063-026-09466-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。